Can gabapentin be given for anxiety in a patient with gastroparesis?

Gabapentin for Anxiety in Gastroparesis Patients

Gabapentin is not recommended for treating anxiety in gastroparesis patients, as it is specifically indicated for visceral pain and neuropathic pain in this population, not anxiety symptoms. 1

Why Gabapentin Is Not the Right Choice for Anxiety

The American Gastroenterological Association's 2022 guidelines clearly position gabapentin as an anticonvulsant for visceral pain management in gastroparesis, not for anxiety treatment. 1, 2 The evidence supporting gabapentin in gastroparesis is limited to:

• Neuropathic pain reduction: Doses >1200 mg daily in divided doses achieved >50% pain reduction compared to placebo in systematic reviews, though selective outcome reporting by industry-sponsored trials has raised concerns about this evidence. 1
• Mechanism: Gabapentin does not address the neurotransmitters involved in anxiety (serotonin and norepinephrine reuptake). 1

Better Options for Anxiety in Gastroparesis

For anxiety specifically in gastroparesis patients, selective serotonin reuptake inhibitors (SSRIs) are the appropriate choice, as they may improve coexisting anxiety and depression, though they won't directly address visceral pain. 1

If the patient has both anxiety and visceral pain, consider:

• Duloxetine (60-120 mg/day): An SNRI that blocks reuptake of both serotonin and norepinephrine, addressing both anxiety and visceral pain, though nausea or constipation can worsen. 1, 3
• Tricyclic antidepressants: Amitriptyline (25-100 mg/day) or nortriptyline (25-100 mg/day) reduce visceral pain perception and may help with anxiety through noradrenaline reuptake inhibition. 1, 3
• Mirtazapine (7.5-30 mg/day): A tetracyclic antidepressant that improved refractory nausea and vomiting in gastroparesis patients and has anxiolytic properties. 1

Critical Context About Gabapentin and Anxiety

Recent evidence raises serious concerns about long-term gabapentinoid use for anxiety:

• Gabapentinoids have tolerance, dependence, addiction, and withdrawal issues similar to benzodiazepines. 4
• Pregabalin deaths in England (244 in 2019) now exceed those from diazepam, fentanyl, tricyclics, or SSRIs as groups, usually involving concomitant opioid use. 4
• Evidence for pregabalin in anxiety derives from short-term trials with marginal differences from placebo, not accounting for long-term tolerance, dependence, and withdrawal. 4

The Anxiety-Gastroparesis Connection

GI-specific anxiety is a distinct phenomenon in gastroparesis that correlates with greater symptom severity (nausea/vomiting, fullness/satiety, upper abdominal pain) and lower quality of life, beyond general anxiety or depression. 5 This suggests that addressing the underlying gastroparesis symptoms may be more effective than treating anxiety in isolation.

Clinical Algorithm

1. Determine if the patient has visceral pain or just anxiety

   • If visceral pain predominates: Consider gabapentin (>1200 mg/day divided) 1, 2
   • If anxiety predominates: Use SSRIs 1
   • If both: Use duloxetine or TCAs 1, 3

2. Avoid medications that worsen gastroparesis: Opioids and GLP-1 agonists significantly exacerbate symptoms. 3

3. Address gastroparesis symptoms directly with antiemetics (ondansetron 4-8 mg bid-tid, granisetron 1 mg bid or 34.3 mg patch weekly) as this may reduce GI-specific anxiety. 1, 3, 5